openPR Logo
Press release

Bipolar Depression market in 7MM is expected to witness a major change in the study period 2019-2032

12-05-2022 11:46 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Bipolar Depression market in 7MM is expected to witness a major

The Bipolar Depression market report provides current treatment practices, emerging drugs, Bipolar Depression (Manic Depression) market share of the individual therapies, current and forecasted Bipolar Depression market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Bipolar Depression market.

Key takeaways from the Bipolar Depression Market Report
• In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM.
• According to DelveInsight, the Bipolar Depression market in 7MM is expected to witness a major change in the study period 2019-2032.
• Bipolar Depression Market Companies are working such as Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others.
• Bipolar Depression Pipeline therapies such as cariprazine, NRX-101, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL) Extended Release, Quetiapine XR, Esketamine DPI - low dose, Lumateperone, Lithium carbonate, and others.

To read more about the latest drug development related to Bipolar Depression, get a snapshot of the key highlights included in the Bipolar Depression Market Outlook @ https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bipolar Depression Overview

Bipolar Depression, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS); the classification is based on the characteristics of mood swings.

Bipolar Depression Epidemiology Segmentation in the 7MM
• Bipolar Depression Patient Pool
• Bipolar Depression Treated Cases

To know more about the Bipolar Depression drugs market growth, get a snapshot of the report Bipolar Depression Market Analysis Report @ https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bipolar Depression Emerging Drugs

Lumateperone: Intra-Cellular Therapies

Lumateperone is a novel second-generation antipsychotic drug. It is marketed under the brand name Caplyta for the treatment of schizophrenia in adults. Lumateperone is in preregistration for the treatment of Bipolar Depression. In May 2022, Intra-Cellular Therapies announced that the US FDA had accepted for review its supplemental New Drug Applications (sNDAs) for lumateperone, for the treatment of depressive episodes associated with bipolar I or II disorder (Bipolar Depression) as monotherapy and as adjunctive therapy with lithium or valproate. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 17, 2022 for the applications.

Zuranolone: SAGE Therapeutics

Zuranolone is an investigational oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). The drug is in Phase II clinical studies for the treatment of Bipolar Depression.

Bipolar Depression Market Outlook

The Bipolar Depression market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Bipolar Depression market trends by analyzing the impact of current Bipolar Depression therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

Read more about the Bipolar Depression treatment market report @
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bipolar Depression Market Research Report
• Coverage- 7MM
• Study Period- 2019-2022
• Forecast Period- 2022-2032
• Bipolar Depression Companies- Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others.
• Bipolar Depression Pipeline Therapies- cariprazine, NRX-101, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL) Extended Release, Quetiapine XR, Esketamine DPI - low dose, Lumateperone, Lithium carbonate, and others.
• Bipolar Depression Market Drivers and Barriers

Table of Content
1. Key Insights
2. Bipolar Depression Executive Summary
3. Bipolar Depression Competitive Intelligence Analysis
4. Bipolar Depression Market Overview at a Glance
5. Bipolar Depression (Manic Depression): Disease Background and Overview
6. Patient Journey
7. Bipolar Depression (Manic Depression) Epidemiology and Patient Population
8. Bipolar Depression Treatment Algorithm, Current Treatment, and Medical Practices
9. Bipolar Depression Unmet Needs
10. Key Endpoints of Bipolar Depression Treatment
11. Bipolar Depression Marketed Products
12. Bipolar Depression (Manic Depression) Emerging Therapies
13. Bipolar Depression (Manic Depression): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Bipolar Depression Market Outlook
16. Access and Reimbursement Overview of Bipolar Depression (Manic Depression)
17. Bipolar Depression KOL Views
18. Bipolar Depression Market Drivers
19. Bipolar Depression Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Learn more about the Bipolar Depression Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bipolar Depression market in 7MM is expected to witness a major change in the study period 2019-2032 here

News-ID: 2834304 • Views:

More Releases from DelveInsight Business Research

Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clinical Trials, Market Share, Therapies, Prevalence, Companies by DelveInsight
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, Market Share, Therapies, Prevalence, Companies by DelveInsight
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indications, and Continued Leadership in HIV Therapy | DelveInsight
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide. As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at a CAGR of 9.39% by 2032, Evaluates DelveInsight
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,

All 5 Releases


More Releases for Depression

Ace Therapeutics Accelerates Preclinical Depression Investigation by Providing D …
Ace Therapeutics released depression-related behavior tests to accelerate preclinical depression research. New York, USA - December 24, 2024 - Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests [https://www.acetherapeutics.com/psychiatry/depression-behavior-tests.html] in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and expedite
Postpartum Depression Global Market Report 2024 - Postpartum Depression Market S …
The Business Research Company recently released a comprehensive report on the Global Postpartum Depression Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The postpartum depression market
Depression Apps Market - Tools for Resilience, Tools for Life: Depression Apps f …
Newark, New Castle, USA: The "Depression Apps Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Depression Apps Market: https://www.growthplusreports.com/report/depression-apps-market/8782 This latest report researches the industry structure, sales, revenue,
Depression Apps Market - Navigating the Path to Mental Wellbeing: Harnessing the …
Newark, New Castle, USA - new report, titled Depression Apps Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Depression Apps market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Depression Apps market. The report offers an overview of the market, which
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive